Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04563026 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
A Phase 2 study, sponsored by Durect.
- Completed
- Registry status
- Phase 2
- Development phase
- 307
- Enrollment target
NCT04563026: Completed Phase 2 study, sponsored by Durect.
NCT04563026 is a Phase 2 study that has completed, run by Durect. The registered enrollment target is 307 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (131% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04563026, a Phase 2 study, has completed, sponsored by Durect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 307 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
Interventions
- DRUG DUR-928 30 mg
- DRUG DUR-928 90 mg
- DRUG Placebo+ Standard of Care (SOC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2021-01-22 |
| Est. Completion | 2023-09-06 |
| Phase | Phase 2 |
What the finished NCT04563026 record still lists
NCT04563026 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (131% higher).
The record links to 0 conditions, and to 3 interventions - of which DUR-928 30 mg is the first listed.
NCT04563026 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04563026 about?
NCT04563026 is a clinical study titled "A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment". This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
What is the current status of trial NCT04563026?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 307 participants. The study started on 2021-01-22. Estimated completion is 2023-09-06.
What interventions are being tested in trial NCT04563026?
The interventions under investigation include: DUR-928 30 mg (DRUG), DUR-928 90 mg (DRUG), Placebo+ Standard of Care (SOC) (DRUG).
Who is sponsoring clinical trial NCT04563026?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04563026's enrollment target sits among peer trials
307 165th of 2000 higher than 1,836 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI